ERBB2 and breast cancer: Current adjuvant treatment strategies for women with HER2-positive breast cancer after their surgery include the use of trastuzumab (H), a humanized monoclonal antibody in combination with anthracyclines (A), taxanes (T) and platinum salts (C).